Article

PDT + triamcinolone shows promise as treatment for non-subfoveal CNV

Short-term results from a small study suggest combined verteporfin (Visudyne,Novartis) photodynamic therapy (PDT) with intravitreal triamcinolone meritsadditional investigation for the treatment of non-subfoveal CNV, said RichardF. Spaide, MD.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
Related Content
Regeneron’s sBLA for Eylea HD accepted for priority review by FDA
April 17th 2025

Regeneron’s sBLA for Eylea HD accepted for priority review by FDA

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Effect of race on visual outcomes in DME treated with ranibizumab
April 17th 2025

Effect of race on visual outcomes in DME treated with ranibizumab

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Aflibercept: Applications for dosing duration and additional indications pending decision with FDA and EMA
April 16th 2025

Aflibercept: Applications for dosing duration and additional indications pending decision with FDA and EMA

Study finds knowledge gaps in public understanding of glaucoma and cataracts
April 16th 2025

Study finds knowledge gaps in public understanding of glaucoma and cataracts

© 2025 MJH Life Sciences

All rights reserved.